

Heinrike Schmeling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1505764/publications.pdf>

Version: 2024-02-01

34
papers

1,017
citations

567281

15
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

1421
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>Parentâ€™Reported</scp> Medication Side Effects and Their Impact on <scp>Healthâ€™Related</scp> Quality of Life in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2022, 74, 1567-1574.	3.4	2
2	Impact of the COVID-19 pandemic on juvenile idiopathic arthritis presentation and research recruitment: results from the CAPRI registry. Rheumatology, 2022, 61, SI157-SI162.	1.9	6
3	Association with HLA-DRÎ²1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. Human Molecular Genetics, 2022, 31, 2471-2481.	2.9	9
4	Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis. Autoimmunity Reviews, 2022, 21, 103086.	5.8	8
5	The <i>iCanCope</i> pain self-management application for adolescents with juvenile idiopathic arthritis: a pilot randomized controlled trial. Rheumatology, 2021, 60, 196-206.	1.9	26
6	Risk factors associated with <i>Pneumocystis jirovecii</i> pneumonia in juvenile myositis in North America. Rheumatology, 2021, 60, 829-836.	1.9	15
7	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology, 2021, 60, 4495-4507.	1.9	15
8	Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet, The, 2021, 398, 1984-1996.	13.7	79
9	Acceptability of an Adolescent Selfâ€™Management Program for Juvenile Idiopathic Arthritis. ACR Open Rheumatology, 2021, , .	2.1	2
10	Functional Ability and Healthâ€™Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2020, 73, 1264-1274.	3.4	4
11	Patient factors associated with waiting time to pediatric rheumatologist consultation for patients with juvenile idiopathic arthritis. Pediatric Rheumatology, 2020, 18, 22.	2.1	9
12	A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. Arthritis Research and Therapy, 2020, 22, 53.	3.5	8
13	A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry. Rheumatology, 2020, 59, 2796-2805.	1.9	12
14	Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care. BMC Health Services Research, 2019, 19, 572.	2.2	7
15	Patientâ€™Reported Barriers at School for Children with Juvenile Idiopathic Arthritis. ACR Open Rheumatology, 2019, 1, 182-187.	2.1	11
16	170â€™fSafety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis. Rheumatology, 2019, 58, .	1.9	0
17	Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis. Frontiers in Immunology, 2019, 10, 745.	4.8	36
18	THU0516â€™...LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	Health-Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. <i>Arthritis Care and Research</i> , 2018, 70, 134-144.	3.4	50
20	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. <i>Pain</i> , 2018, 159, 57-66.	4.2	29
21	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. <i>Pediatric Rheumatology</i> , 2017, 15, 68.	2.1	39
22	Management of Juvenile Idiopathic Arthritis 2015: A Position Statement from the Pediatric Committee of the Canadian Rheumatology Association. <i>Journal of Rheumatology</i> , 2016, 43, 1773-1776.	2.0	23
23	Anti-HMGR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	5.8	105
24	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1092-1098.	0.9	72
25	Development of System-level Performance Measures for Evaluation of Models of Care for Inflammatory Arthritis in Canada. <i>Journal of Rheumatology</i> , 2016, 43, 530-540.	2.0	63
26	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1854-1860.	0.9	192
27	Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. <i>Journal of Rheumatology</i> , 2015, 42, 2419-2426.	2.0	34
28	A38: Twelve Years' Experience with Etanercept in the Treatment of Juvenile Idiopathic Arthritis: How It Has Changed Practice-The German Biologics JIA Registry (BiKeR). <i>Arthritis and Rheumatology</i> , 2014, 66, S58-S58.	5.6	3
29	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014, 66, S17-S18.	5.6	4
30	A39: Efficacy and Safety of Methotrexate in Oligoarticular Persistent Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, S59-S59.	5.6	5
31	Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 682-690.	8.0	17
32	Purpura, petechiae, and bullae as first signs of juvenile granulomatosis with polyangiitis. <i>European Journal of Pediatrics</i> , 2014, 173, 1685-1689.	2.7	2
33	Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry. <i>Arthritis and Rheumatology</i> , 2014, 66, 2580-2589.	5.6	69
34	Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. <i>Rheumatology</i> , 2011, 50, 885-893.	1.9	61